T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Akamai
AKAM
$17B
| $1.11B | 0.24% |
18,181,145
-3,468,657
| -16% | -$193M |
|
|
PX
102
DELISTED
Praxair Inc
PX
| $1.1B | 0.24% |
8,281,459
-4,401,300
| -35% | -$577M |
|
103
Phillips 66
PSX
$88.6B
| $1.08B | 0.23% |
13,455,728
-565,986
| -4% | -$46.6M |
|
104
3M
MMM
$94.5B
| $1.08B | 0.23% |
8,996,058
+326,948
| +4% | +$38.4M |
|
105
Kohl's
KSS
$2.1B
| $1.07B | 0.23% |
20,297,362
+24,790
| +0.1% | +$1.34M |
|
106
Cisco
CSCO
$477B
| $1.06B | 0.23% |
42,785,736
-3,693,938
| -8% | -$88M |
|
107
Northern Trust
NTRS
$34.5B
| $1.06B | 0.23% |
16,438,104
-302,080
| -2% | -$18.6M |
|
108
Tractor Supply
TSCO
$18.7B
| $1.04B | 0.22% |
85,833,885
+7,837,725
| +10% | +$103M |
|
109
MetLife
MET
$61.5B
| $1.03B | 0.22% |
20,828,268
+1,337,084
| +7% | +$62.6M |
|
110
Idexx Laboratories
IDXX
$46.5B
| $1.03B | 0.22% |
15,429,340
-1,204,868
| -7% | -$76.6M |
|
|
TYC
111
DELISTED
TYCO INTL PLC COM SHS (IRL)
TYC
| $1.03B | 0.22% |
21,544,395
+1,727,855
| +9% | +$77.9M |
|
112
NiSource
NI
$19.9B
| $1.03B | 0.22% |
66,367,072
+3,368,147
| +5% | +$48.7M |
|
113
Xcel Energy
XEL
$48B
| $1.02B | 0.22% |
31,785,220
+2,554,040
| +9% | +$79.1M |
|
114
ASML
ASML
$691B
| $1.02B | 0.22% |
10,891,300
+1,195,977
| +12% | +$103M |
|
115
MGM Resorts International
MGM
$11B
| $1.01B | 0.22% |
38,292,368
+4,097,276
| +12% | +$102M |
|
116
Carnival Corporation Ltd
CCL
$38.4B
| $1.01B | 0.22% |
26,715,665
+1,262,064
| +5% | +$48.9M |
|
117
CNX Resources
CNX
$5.3B
| $997M | 0.22% |
25,980,800
-4,776,609
| -16% | -$175M |
|
118
Archer Daniels Midland
ADM
$38.3B
| $979M | 0.21% |
22,191,527
-566,221
| -2% | -$25M |
|
119
General Motors
GM
$78.4B
| $973M | 0.21% |
26,805,015
+708,113
| +3% | +$24.7M |
|
120
ServiceNow
NOW
$132B
| $973M | 0.21% |
78,509,085
+9,613,540
| +14% | +$103M |
|
121
Exelon
EXC
$46B
| $968M | 0.21% |
37,211,137
+2,997,806
| +9% | +$76.4M |
|
122
Vulcan Materials
VMC
$37.1B
| $959M | 0.21% |
15,044,281
-75,655
| -0.5% | -$4.79M |
|
123
Intercontinental Exchange
ICE
$84.2B
| $954M | 0.21% |
25,253,750
+2,547,015
| +11% | +$99.3M |
|
124
Wabtec
WAB
$50.1B
| $930M | 0.2% |
11,255,808
+1,864,541
| +20% | +$144M |
|
125
Johnson Controls International
JCI
$92.7B
| $927M | 0.2% |
17,737,562
+1,995,407
| +13% | +$99.2M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.